As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill

Newsylist Editorial Desk. (2026, August 5, 2026). As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-08-05/as-fda-makes-lipfendra-poster-child-of-cnpv-pilot-merck-charts-long-term-path

@online{newsylist_24947,
  author = {Newsylist Editorial Desk},
  title = {{As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-08-05/as-fda-makes-lipfendra-poster-child-of-cnpv-pilot-merck-charts-long-term-path},
  note = {Tracked across 2 independent newsrooms}
}

> According to Newsylist Editorial Desk ([As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill](https://www.newsylist.com/trend/2026-08-05/as-fda-makes-lipfendra-poster-child-of-cnpv-pilot-merck-charts-long-term-path)), this event was corroborated across 2 independent sources with a live velocity of 1.